Dr. Bowman On Rationale For Radio-Labeled Atezolizumab Pet/Ct Scans In Rcc

Dr. Bowman on Rationale for Radio-Labeled Atezolizumab PET/CT Scans in RCC

Dr. Atkins on Results of Atezolizumab Plus Bevacizumab in RCC

ABACUS updates: positive results for preoperative atezolizumab in bladder cancer

Case-Based Tumor Board: Confronting Management Controversies in Renal Cell Carcinoma

Grand Rounds in Urology

Exploring MEDI0680/Durvalumab Versus Nivolumab in Metastatic ccRCC

Targeted Oncology

Virtual Biopsy of Renal Masses

Health4TheWorld Academy

Dr. Zibelman on Determining Treatments for Patients with RCC

Dr. O’Hara on Rationale for APX005M/Chemotherapy and Nivolumab in Pancreatic Cancer

Dr. Boorjian on Research With Nadofaragene Firadenovec in Nonmuscle Invasive Bladder Cancer

Debate: Should PET scan be used for optimal follow-up in metastatic NSCLC? - Yes

Discussing the Phase II Study of Lenvatinib/Pembrolizumab in Metastatic ccRCC

Targeted Oncology

Dr. Bekaii-Saab on the Addition of Atezolizumab to Capecitabine/Bevacizumab in MSS mCRC

Dr. Knudsen Discusses the Rationale of the DALIAH Trial in MPNs

Copy of Dr. Hamilton on FDA Approval of Atezolizumab/Nab-Paclitaxel in TNBC

What is renal cell carcinoma?

European Radiosurgery Center Munich

Dr. Vulfovich on Broad Molecular Profiling in mCRC

Treatment response assessment in melanoma and the challenge of pseudoprogression with immunotherapy

The agents at the forefront of kidney cancer treatment

Dr. Albiges on Implementing mRCC Findings into Practice

Copy of Dr. McGregor on Implications of the FDA Approval of Pembrolizumab/Axitinib in RCC